Lv11
90 积分 2024-01-16 加入
c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer
9天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
10天前
已完结
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
10天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
10天前
已完结
Ribociclib plus Endocrine Therapy in Early Breast Cancer
10天前
已完结
Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4/6 inhibitors: A comprehensive review
14天前
已完结
Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation
14天前
已完结
Emerging Targeted Therapies for Early Breast Cancer
14天前
已完结
Tissue Specificity of DNA Damage and Repair
16天前
已完结
When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity
16天前
已完结
皖公网安备34019202002308
